Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 7,478 shares, an increase of 72.8% from the December 15th total of 4,327 shares. Based on an average trading volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 75,968 shares, the days-to-cover ratio is presently 0.1 days.

Barinthus Biotherapeutics Trading Down 0.6%

Shares of Barinthus Biotherapeutics stock opened at $0.75 on Thursday. The stock’s fifty day moving average price is $0.75 and its 200-day moving average price is $1.09. The firm has a market cap of $30.82 million, a P/E ratio of -0.40 and a beta of -0.66. Barinthus Biotherapeutics has a 12 month low of $0.64 and a 12 month high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its earnings results on Friday, November 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09. Analysts forecast that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. boosted its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 as of its most recent filing with the Securities & Exchange Commission. 25.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BRNS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. HC Wainwright lifted their price objective on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a report on Monday, November 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.